Gemfibrozil and Coronary Heart Disease
- 12 May 1988
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 318 (19) , 1274-1275
- https://doi.org/10.1056/nejm198805123181913
Abstract
To the Editor: The Helsinki Heart Study (Nov. 12 issue)1 is the third major trial in which cholesterol levels have been lowered by the use of drugs. The other two were the World Health Organization clofibrate study and the Lipid Research Clinics trial of cholestyramine.2 , 3 In all these studies the incidence of ischemic heart disease was reduced, as was mortality from the disorder, but total mortality in the intervention group was as high as in the control group.An unexplained but now consistent finding is a larger number of deaths from "other causes" in the intervention studies. In particular, there . . .Keywords
This publication has 7 references indexed in Scilit:
- Gemfibrozil, Lipids, and Coronary RiskNew England Journal of Medicine, 1987
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJournal of the American College of Cardiology, 1986
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart diseaseJAMA, 1984
- A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.Heart, 1978
- CANCER AMONG MEN ON CHOLESTEROL-LOWERING DIETS: Experience from Five Clinical TrialsThe Lancet, 1971
- INCIDENCE OF CANCER IN MEN ON A DIET HIGH IN POLYUNSATURATED FATThe Lancet, 1971